Immunotherapy advancements and side effect management in cancer treatment

Immunotherapy is fundamentally altering survival rates for patients with advanced cancer by directing the body's own immune system to target tumor cells. Malignant cells often exploit biological safeguards, such as the PD-1 protein, to signal the immune system to stand down. Immunotherapy drugs, specifically checkpoint inhibitors, work by blocking these inhibitory functions, allowing natural immune cells to recognize and attack the malignancy.

Commonly used checkpoint inhibitors include Keytruda, Opdivo, Tecentriq, Imfinzi, and Libtayo. While effective, these treatments can cause immune-related adverse events where the heightened immune response inflames healthy organs.

Frequent side effects include skin rashes and itching, affecting up to 70 percent of patients in some studies. Additionally, inflammation of the colon, known as colitis, affects between 8 percent and 27 percent of patients. Unlike chemotherapy-induced diarrhea, immunotherapy-related colitis is driven by the immune system and requires specific medical management to prevent complications.